# US 2025/0367125 A1 · Oral polypeptide composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367125 A1
- Document ID: US20250367125A1
- Status: Published application
- Kind: A1
- Application number: 19/194,059
- Filed: 2025-04-30
- Published: 2025-12-04
- Earliest claimed: 2024-06-03
- Assignees: Shenzhen Oralead Pharma Co., LTD.
- Applicants: Shenzhen Oralead Pharma Co., LTD.
- Inventors: Banghao YUAN; Yusheng Sui; Liu Dou
- Web page: https://patentgrep.com/patent/US20250367125A1

## CPC

- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 38/26: Glucagons
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An oral polypeptide composition for improving the gastrointestinal absorption of polypeptide drugs is provided. The oral polypeptide composition includes polypeptide molecules, medium-chain fatty acids (MCFA) and their salts, amino acids and N-(8-(2-hydroxybenzoyl) amino) caprylic acid (NAC) and its salts. The oral polypeptide composition can effectively increase the plasma drug concentration of the polypeptide and improve the oral bioavailability of the polypeptide.

## Claims

### Claim 1

An oral polypeptide composition, wherein the oral polypeptide composition comprises: a polypeptide targeting the GLP-1 receptor, one or more amino acids present as individual components, N-(8-[2-hydroxybenzoyl]-amino) caprylic acid (NAC) or a salt thereof, and medium-chain fatty acids or a salt thereof; a total content of the one or more amino acids, the NAC or salt thereof, and the medium-chain fatty acid or a salt thereof in the oral polypeptide composition is 50-90% w/w.

### Claim 2 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises no more than 20% w/w of the one or more amino acids.

### Claim 3 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises no more than 55% w/w of the NAC or a salt thereof.

### Claim 4 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises no less than 10% w/w of the medium-chain fatty acid or a salt thereof.

### Claim 5 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises no more than 15% w/w of the polypeptide targeting the GLP-1 receptor.

### Claim 6 (depends on 1)

The oral polypeptide composition according to claim 1, wherein a mass ratio of the one or more amino acids, the NAC or salt thereof, and the medium-chain fatty acid or a salt thereof is 1:(2.5-3.5):(2.5-3.5).

### Claim 7 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the polypeptide is semaglutide.

### Claim 8 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises: semaglutide, about 10-20% w/w of the one or more amino acids, 20-50% of the NAC or the salt thereof, and no less than 15% w/w of the medium-chain fatty acid or a salt thereof; wherein the total content of the one or more amino acids, the NAC or salt thereof, and the medium-chain fatty acid or a salt thereof in the oral polypeptide composition is 70-80% w/w.

### Claim 9 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the salt of the medium-chain fatty acid is sodium caprate.

### Claim 10 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the one or more amino acids comprising nitrogen in a side chain are selected from lysine, arginine, asparagine, glutamine, tryptophan, ornithine, citrulline, pyrrolysine, or histidine.

### Claim 11 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the salt of the NAC is sodium N-(8-(2-hydroxybenzoyl) amino) caprylate (SNAC).

### Claim 12 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition further comprises no more than 30% w/w of excipients.

### Claim 13 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises:
1-50 pbw of semaglutide;
15-100 pbw of arginine;
100-300 pbw of sodium caprate;
100-300 pbw of SNAC; and
40-180 pbw of excipients.

### Claim 14 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises: 4.0 mg semaglutide, 50.0 mg arginine, 150.0 mg SNAC, 150.0 mg sodium caprate, and 126.0 mg excipients.

### Claim 15 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises: 8.0 mg semaglutide, 50.0 mg arginine, 150.0 mg SNAC, 150.0 mg sodium caprate, and 122.0 mg excipients.

### Claim 16 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition comprises: 16.0 mg semaglutide, 50.0 mg arginine, 150.0 mg SNAC, 150.0 mg sodium caprate, and 114.0 mg excipients.

### Claim 17 (depends on 1)

The oral polypeptide composition according to claim 1, wherein the oral polypeptide composition is a solid preparation.

### Claim 18 (depends on 17)

The oral polypeptide composition according to claim 17, wherein the oral polypeptide composition is tablets, capsules, granules, powders, granules, pellets, or pills.

### Claim 19 (depends on 18)

The oral polypeptide composition according to claim 18, wherein a specification of the tablets is 1-50 mg.

### Claim 20 (depends on 1)

A method for preventing and/or treating a disease, comprising administering the oral polypeptide composition according to claim 1 to a subject in need; wherein the disease is selected from at least one of type 1 diabetes, type 2 diabetes, obesity, cardiovascular disease, non-alcoholic fatty liver disease, chronic kidney disease, Alzheimer's disease, cancer, polycystic ovary syndrome, metabolic syndrome, bone metabolism and osteoporosis, knee osteoarthritis, sleep apnea syndrome, osteoarthritis, and metabolic muscle disease.
